China Medicine Corp. (CHME.OB) Enters Into $69.6M Stock Subscription Agreement with One Equity Partners
China Medicine Corp. today announced entrance into a Stock Subscription Agreement (the “Agreement”) with One Equity Partners (OEP) for an equity private placement. This marks the first major investment by OEP, which is the global private equity investment arm of JPMorgan Chase & Co. in China, and is accordant with the firm’s strategy of developing aspiring management teams. Registered in Delaware, CHME develops and distributes a number of proprietary pharmaceuticals to wholesalers worldwide, including prescription and over-the-counter (OTC) drugs, as well as nutraceuticals, devices and traditional Chinese medicine products such as formulations, herbs and supplements. Under terms of the Agreement,…